<DOC>
	<DOCNO>NCT01305941</DOCNO>
	<brief_summary>Purpose : This study single-arm , open-label phase II clinical trial test hypothesis daily everolimus plus weekly vinorelbine trastuzumab effective , safe , tolerable among patient HER2-positive breast cancer brain metastasis . Once enrolled , patient receive everolimus PO daily combination weekly intravenous ( IV ) vinorelbine trastuzumab . Cycles repeat every 3 week ( 21 day ) . At time progression , patient come study . Participants : Up 35 adult 21 HER-2 positive breast cancer metastasize brain .</brief_summary>
	<brief_title>A Study Of Everolimus , Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases</brief_title>
	<detailed_description>STUDY OBJECTIVES Primary Objective -To determine intracranial objective response rate mTOR inhibition ( everolimus ) combination vinorelbine trastuzumab treatment HER2-positive , progressive breast cancer brain metastasis define via modify RECIST criterion . Secondary Objectives - To determine intracranial objective response rate mTOR inhibition ( everolimus ) combination vinorelbine trastuzumab treatment HER2-positive , progressive breast cancer brain metastasis define MacDonald criterion . - To evaluate safety tolerability everolimus combination trastuzumab vinorelbine assess via NCI CTCAE version 4.0 - To evaluate time intracranial progression administration everolimus combination trastuzumab vinorelbine define via modified RECIST criterion - To evaluate extracranial objective response rate determine RECIST 1.1 criterion administration everolimus combination trastuzumab vinorelbine . - To evaluate extracranial time progression determine RECIST 1.1 criterion administration everolimus combination trastuzumab vinorelbine . - To evaluate progression free survival ( PFS ) overall survival ( OS ) administration everolimus combination trastuzumab vinorelbine . - To evaluate impact everolimus combination trastuzumab vinorelbine quality life measure FACT-B FACT-Br questionnaire . Exploratory Objective -To evaluate biomarkers archival tumor tissue sample correlate therapeutic response everolimus combination vinorelbine trastuzumab . Following Hepatitis B antiviral prophylaxis require , follow screening informed consent antiviral therapy need , treatment initiate everolimus PO daily combination weekly intravenous ( IV ) vinorelbine trastuzumab ( Days 1 , 8 , 15 ) A cycle define 3 week ( 21 day ) . Cycles therapy repeat documented disease progression , unacceptable toxicity , patient withdrawal study reason , include death .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion Criteria Histologicallyconfirmed HER2positive ( IHC 3+ fluorescence situ hybridization [ FISH ] amplify ; clinical assay either primary metastatic tumor ) adenocarcinoma breast least one progressive and/or new metastatic brain lesion ( &gt; /=5 mm radiographic imaging ) receipt intracranial radiation therapy ( whole brain radiation therapy , stereotactic radiosurgery , gamma knife , equivalent ) . Patients BM asymptomatic detect routine brain MRI screen per institutional protocol eligible . Prior intracranial radiation therapy ( whole brain radiation therapy , stereotactic radiosurgery , gamma knife equivalent ) allow require . Patients prior treatment ICR may include unless ICR emergently indicate ( consultation local therapist , ie neurosurgeon radiation oncologist ) ECOG performance status 02 . Life expectancy &gt; 12 week . At least 21 year age . No prior mTOR inhibitor Prior navelbine allow provided navelbine therapy discontinue &gt; /= 12 month Day 1 treatment protocol . Last anticancer treatment ( include investigational drug ) &gt; /= 2 week initiation protocol base therapy , provide AEs ( alopecia ) resolve ≤grade 1 baseline . No active serious infection comorbid illness would impair ability participate trial . Left ventricular ejection fraction assessment ( echocardiogram MUGA scan ) perform within 4 week prior study initiation , show LVEF value ≥ low limit normal ( LLN ) . If patient dexamethasone , must stable decrease dose dexamethasone ≥7 day . If patient different glucocorticoid e.g. , prednisone , must convert dexamethasone prior enrollment . Refer dose modification everolimus patient take dexamethasone . Interval ≥4 week open brain biopsy initiation protocolbased therapy . INR ≤2.0 . Anticoagulation allow target INR ≤2.0 stable dose warfarin patient stable dose LMW heparin &gt; 1 week time enrollment . Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤2.5 x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication . Patients must adequate organ function evidence : Absolute neutrophil count ≥1.5/µL Platelet count ≥100,000/µL Hg ≥9 g/dL Bilirubin ≤1.5 x upper limit normal ( ULN ) AST ALT ≤2.5 x ULN ( ≤5 x ULN liver metastasis present ) Serum creatinine ≤1.5 x ULN Archived , paraffinembedded tissue block ( primary metastatic ) available genomic study require . Signed , IRBapproved write informed consent . Exclusion Criteria Patients receive prior treatment mTOR inhibitor ( e.g. , sirolimus , temsirolimus , everolimus ) ; patient receive prior treatment navelbine within prior 12 month . patient know hypersensitivity everolimus rapamycins ( e.g . sirolimus , temsirolimus ) excipients . Patients require treatment systemic glucocorticoid . NOTE : This restriction regard choice glucocorticoid apply patient need &lt; 2 week course glucocorticoid treatment noninfectious pneumonitis study ( see section 4.5.2 ) . Patients know hypersensitivity vinorelbine excipients . Prior allergic reaction trastuzumab treatment metastatic breast cancer . Concurrent plan radiation , hormonal , chemotherapeutic , experimental target biologic therapy . Peripheral neuropathy ≥grade 3 . Evidence frank hemorrhage impend herniation baseline brain imaging.NOTE : asymptomatic microhemorrhage allow . Evidence diffuse leptomeningeal disease brain MRI previously document CSF cytology . NOTE : discrete dural metastasis permit . Active cardiac disease include follow : Angina pectoris require use antianginal medication ; Ventricular arrhythmias except benign premature ventricular contraction ; Supraventricular nodal arrhythmia require pacemaker control medication ; Conduction abnormality require pacemaker ; Valvular disease document compromise cardiac function ; Symptomatic pericarditis History cardiac dysfunction include one following : Myocardial infarction document elevated cardiac enzyme persistent regional wall abnormality assessment LV function ; History document congestive heart failure ( New York Heart Association functional classification IIIIV ) ; Documented cardiomyopathy Patients major surgery significant traumatic injury within 4 week start study drug , patient recover side effect major surgery ( define require general anesthesia ) , patient may require major surgery course study . Patients receive immunization attenuate live vaccine within 1 week study entry study period . Close contact receive attenuated live vaccine avoid treatment everolimus . Examples live vaccine include intranasal influenza , measles , mumps , rubella , oral polio , BCG , yellow fever , varicella , TY21a typhoid vaccine . Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin . Patients severe and/or uncontrolled medical condition condition could affect participation study : severely impaired lung function , define spirometry diffusion lung capacity carbon monoxide ( DLCO ) 50 % normal predict value and/or 02 saturation ≤88 % rest room air uncontrolled diabetes , define fast serum glucose &gt; 1.5 x ULN ( Note : Optimal glycemic control achieve start trial therapy ) active ( acute chronic ) uncontrolled severe infection liver disease cirrhosis severe hepatic impairment ( ChildPugh class C ) . Note : A detailed assessment Hepatitis B/C medical history risk factor must do screening patient . HBV DNA HCV RNA PCR test require screening patient positive medical history base risk factor and/or confirmation prior HBV/HCV infection . A known history HIV seropositivity . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . Patients active , bleed diathesis oral antivitamin K medication ( except lowdose warfarin aspirin equivalent , long INR ≤2.0 ) . Unable unwilling discontinue use prohibit fruit ( juice ) prohibit medication list Appendices II III least 14 day 5 halflives drug ( whichever longer ) prior first dose study drug duration study . Female patient pregnant breastfeeding , adult reproductive potential use effective birth control method . Adequate contraception must use throughout trial 8 week last dose study drug , sex . Women childbearing potential ( WOCBP ) must negative urine serum pregnancy test within 7 day prior everolimus initiation . Male patient whose sexual partner ( ) WOCBP willing use adequate contraception , study 8 week end treatment Contraindication gadoliniumenhanced MRI image . Inability comply study and/or followup procedure . History noncompliance medical regimen .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>everolimus</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>RAD001</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Navelbine</keyword>
	<keyword>Lineberger Comprehensive Cancer Center</keyword>
	<keyword>Brain Metastases</keyword>
</DOC>